Wiley-VCH, Weinheim Tumor-Associated Antigens Cover This very first comprehensive resource on the topic covers basic knowledge, identification technolog.. Product #: 978-3-527-32084-4 Regular price: $95.33 $95.33 Auf Lager

Tumor-Associated Antigens

Identification, Characterization, and Clinical Applications

Gires, Olivier / Seliger, Barbara (Herausgeber)

Cover

1. Auflage März 2009
XXI, 362 Seiten, Hardcover
11 Abbildungen (8 Farbabbildungen)
16 Tabellen
Handbuch/Nachschlagewerk

ISBN: 978-3-527-32084-4
Wiley-VCH, Weinheim

Wiley Online LibraryInhaltProbekapitelIndex

Kurzbeschreibung

This very first comprehensive resource on the topic covers basic knowledge, identification technologies as well as examples of successful clinical application. A must-have for biologists and oncologists in science, clinics and industry.

Jetzt kaufen

Preis: 102,00 €

Preis inkl. MwSt, zzgl. Versand

Euro-Preise für Wiley-VCH- und Ernst & Sohn-Titel sind nur für Deutschland gültig. In EU-Ländern gilt die lokale Mehrwertsteuer. Portokosten werden berechnet.

- Gedruckte Ausgabe vergriffen -

Weitere Versionen

pdf

Alles, was man gegenwärtig über tumorassoziierte Antigene (TAA) und ihre Typen weiß, wurde in diesem hochaktuellen Handbuch zusammengefasst. Die Beiträge gehen auf Grundlagen, Verfahren zur Identifikation von TAAs und vielfältige medizinische Anwendungen ein; betont wird die Notwendigkeit einer präzisen, im klinischen Umfeld validierten Funktionsanalyse. Abgerundet wird der Text durch einen Überblick über alle gegenwärtig zu therapeutischen Zwecken zugelassenen Antikörper.

TUMOUR-ASSOCIATED ANTIGENS (TAAS): SUBCLASSES OF TAAS
T cell Antigens in Cancer (A. Paschen)
Human Tumour Antigens, Immunosurveillance, and Cancer Vaccines (O.J. Finn)
METHODS TO DETECT TAAS
Humoral Antigens in Cancer: Serological Identification Methods, Part I: SEREX (M. Pfreundschuh)
Humoral Antigens in Cancer: Serological Identification Methods, Part II: Proteomex and AMIDA (B. Seliger, O. Gires)
cDNA and Microarray-Based Technologies (F. Marincola, Ena Wang)
Detection and Identification of TAA by SELDI-TOF (F. von Eggeling, C. Melle)
TAAS AND THEIR USEFULNESS
Minor Histocompatibility Antigens and TAAs for Pediatric Cancers (U. Behrends, J. Mautner)
TAAs and their Regulation/Epigenetics (M. Maio)
Cancer-Testis Antigens (CT-antigens) (J.S. Cebon)
Animal Models for TAAs (P. McLaughlin)
Epithelial Cell Adhesion Molecule EpCAM in cancer (CD326) (P.A Baeuerle, G. Riethmüller)
Carcinoembryonic Antigen CEA (W. Zimmermann, R. Kammerer)
Her2/neu and Herceptin (B. Seliger)
Epstein-Barr Virus (EBV) Tumour-Associated Antigens (C. Mancao, W. Hammerschmidt)
Human Papilloma Virus (HPV) Tumour-Associated Antigens (A. Kaufmann)
Circulating TAAs: Biomarkers for Ovarian Cancer Diagnosis (E. Seregni, E. Bombardieri)
CLINICAL APPLICATIONS OF TAAS
Cancer Vaccines (A. Dalgleish)
Peptide Vaccination (D.P. Fairlie)
DNA Vaccination: Human Papilloma Virus (T.C. Wu)
Adoptive T cell transfer (A. Moosmann, A. Krackhardt)

Olivier Gires is a group leader at the ENT research department, Munich Medical Center, Germany and leading head of the Clinical Cooperation Group Molecular Oncology at the GSF. In 1999, he obtained his PhD in biology for his work on Epstein-Barr virus´ oncoprotein LMP1. Thereafter, Olivier Gires focused on the identification and molecular characterization of tumor-associated antigens with particular emphasis on the elucidation of the function of the therapeutic target EpCAM. Work by his group unraveled the oncogenic potential of EpCAM along with underlying molecular mechanisms. Additionally, he was decisively involved in the development of the target identification technology AMIDA.

B. Seliger, Martin-Luther-University, Halle, Germany